Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
Data included results for 42 women at Day 35, 7 days after the last dose of VTP-200.
- Data included results for 42 women at Day 35, 7 days after the last dose of VTP-200.
- The final dataset, including data on clearance of infection and cervical lesions at 12 months post-treatment, is expected in the second quarter of 2024.
- Revenue: Revenue consisted of $0.3 million in the second quarter of 2023 compared to $0.5 million in the first quarter of 2023.
- Research and development expenses: Research and development expenses were $13.5 million in the second quarter of 2023 compared to $9.8 million in the first quarter of 2023, showing increased spend due to phasing of clinical and pre-clinical trials.